The financials
Indivior Pharmaceuticals, Inc. by the numbers
Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $343M in Q2 2026 (quarter ended June 30, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 86% and net income of $122M (36% of revenue). For the full year FY2025, revenue was $1.24B (+4.3% year on year) and net income $210M. Its largest product in 2026-Q2 was Sublocade at $238M, 79% of the disclosed total, just ahead of Sublingual And Other at 19%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $343M | $302M | +14% |
| Gross profit | $294M | $250M | +18% |
| Operating income | $160M | $72M | +122% |
| Net income | $122M | $18M | +578% |
| Diluted EPS | $0.98 | $0.14 | +600% |
| Product | Revenue | Share |
|---|---|---|
| Sublocade | $238M | 79% |
| Sublingual And Other | $57M | 19% |
| Perseris | $5.0M | 1.7% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $300.0M (+9.9%)
Sublocade grew +22% year on yearPerseris -38% year on year
Segment Latestquarter on quarteryear on year
- Sublocade$238.0M$238.0MQoQ +9.2%year on year +22%+9.2%+22%
- Sublingual And Other$57.0M$57.0MQoQ +14%year on year +9.6%+14%+9.6%
- Perseris$5.0M$5.0MQoQ 0.00%year on year -38%0.00%-38%
Drug Manufacturers - Specialty & Generic
Ranks #23 of 28 by Smart Score